EDITOR'S DESK

Is Biopharma’s Response To Coronavirus Off The Mark?

As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.

COVID-19: A Case For “Virtual” Biopharma?

Work-and-learn from home policies are more than employee perks. They could help thwart a pandemic. Have you adopted procedures and tools that ensure continuity when employees aren’t in the office?

The Process Behind The Potential: Therapy For HPV16-Related Malignancies

HPV-related malignancies are poised to skyrocket over the next thirty+ years. Here's a look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation to treat these cancers.

Update On Advanced Rapid Microbiology Methods In Biopharma

A BioPhorum survey of biopharma end-users reveals the opportunity—and the challenge—involved in the adoption of advanced rapid microbiology methods. Audrey Chang, global head of development services at BioReliance Merck; Morven McAlister, senior director at Pall Biotech; and Scott Hooper, associate director at Merck & Co Inc. break down the data.

GUEST COLUMNISTS

BIOPROCESSING WHITE PAPERS

BIOPROCESS ONLINE CONTENT COLLECTIONS

19_09_BPO_PotentCompoundsEbook_300x200

 

This e-book shares some of our experiences in the more hazardous areas, and in turn challenges you to look at your facilities and operations to apply some basic safe design philosophies to whatever you are working with, potent or not. We sincerely hope you enjoy them and continue to be safe.

More Content Collections

LIFE SCIENCE INDUSTRY EVENTS

TRAINING COURSES